Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent and Trademark Office (USPTO) issued paten ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results